Ryoko Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryoko Sato has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Daniel A. Hamstra
Radiation Oncology, Baylor College of Medicine, Houston, USA
2 shared publicationsJames B. Yu
Department of Radiation Oncology, Dartmouth Hitchcock Medical Center, Hanover, USA
2 shared publicationsMichael R. Folkert
Department of Radiation Oncology, University of Washington School of Medicine, Seattle, USA
2 shared publicationsSamir Bhattacharyya
Boston Scientific, Marlborough, USA
2 shared publicationsAbimbola O. Williams
Boston Scientific, Marlborough, Massachusetts
1 shared publicationAlexander C. Fanaroff
University of Pennsylvania, Penn Medicine, Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by Elmer Press, Inc. in Journal of Clinical Gynecology and Obstetrics
- Vol. 14 (3) , 75-83
Socioeconomic, Demographic, and Provider Determinants of Staged Versus Concomitant Surgery for Pelvic Organ Prolapse and Stress Urinary Incontinence
Background: While concomitant surgery for pelvic organ prolapse (POP) and stress urinary incontinence (SUI) may benefit patients, variability exists in practice. A better understanding of the decision-making process regarding the placement of mid-urethral slings (MUSs) in women undergoing POP surgery is crucial for achieving equitable surgical planning and patient counselling. This study assessed factors associated with staged vs. concomitant SUI surgery in patients undergoing POP surgery. Methods: This retrospective cohort study used 100% Medicare Standard Analytical Files from 2016 to 2020. The sample population consisted of female patients surgically treated for POP with staged (within 24 months) or concomitant mid-urethral sling (MUS). Data were merged with the Agency for Healthcare Research and Quality (AHRQ) Social Determinants of Health Database. Multivariable logistic regression was used to assess independent associations between patient, location, and surgeon characteristics and the likelihood of staged versus concomitant procedures. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Results: Among 40,842 patients with POP surgery, 96.7% (39,440) had concomitant, while 3.4% (1,402) had staged MUS. Most were aged 65 - 74 years (67.2%), Caucasian (91.7%), from urban areas (91.9%), and had Charlson Comorbidity Index ≤ 3 (82.3%). A higher likelihood of staged surgery was seen in White vs. other racial groups (example OR: 1.50 vs. Black, 95% CI: 1.03 - 2.18); in the South vs. other regions (example OR: 1.55 vs. Northeast, 95% CI: 1.26 - 1.91); and for obstetrics/gynecology vs. urologic surgeons (OR: 1.19, 95% CI: 1.02 - 1.40). Patients in counties with lower per capita income (OR: 1.02, 95% CI: 1.01 - 1.03), lower proportions of foreign-born (OR: 1.01, 95% CI: 1.01 - 1.05), limited English-speaking (OR: 1.03, 95% CI: 1.01 - 1.05), or uninsured (< 64 years of age; OR: 1.02, 95% CI: 1.00 - 1.03) households had higher likelihood of receiving staged surgery. Conclusions: This study identified several demographic, socioeconomic, and surgeon-related factors associated with staged vs. concomitant MUS procedures among patients undergoing surgery for POP. The reasons for these differences are not fully understood and may reflect various underlying factors, including differences in communication, regional or specialty norms, patient choice, or other factors.
- 1 October 2025
- Published by Elmer Press, Inc. in Journal of Clinical Gynecology and Obstetrics
- Vol. 14 (3) , 75-83
Open AccessSocioeconomic, Demographic, and Provider Determinants of Staged Versus Concomitant Surgery for Pelvic Organ Prolapse and Stress Urinary Incontinence
Background: While concomitant surgery for pelvic organ prolapse (POP) and stress urinary incontinence (SUI) may benefit patients, variability exists in practice. A better understanding of the decision-making process regarding the placement of mid-urethral slings (MUSs) in women undergoing POP surgery is crucial for achieving equitable surgical planning and patient counselling. This study assessed factors associated with staged vs. concomitant SUI surgery in patients undergoing POP surgery. Methods: This retrospective cohort study used 100% Medicare Standard Analytical Files from 2016 to 2020. The sample population consisted of female patients surgically treated for POP with staged (within 24 months) or concomitant mid-urethral sling (MUS). Data were merged with the Agency for Healthcare Research and Quality (AHRQ) Social Determinants of Health Database. Multivariable logistic regression was used to assess independent associations between patient, location, and surgeon characteristics and the likelihood of staged versus concomitant procedures. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Results: Among 40,842 patients with POP surgery, 96.7% (39,440) had concomitant, while 3.4% (1,402) had staged MUS. Most were aged 65 - 74 years (67.2%), Caucasian (91.7%), from urban areas (91.9%), and had Charlson Comorbidity Index ≤ 3 (82.3%). A higher likelihood of staged surgery was seen in White vs. other racial groups (example OR: 1.50 vs. Black, 95% CI: 1.03 - 2.18); in the South vs. other regions (example OR: 1.55 vs. Northeast, 95% CI: 1.26 - 1.91); and for obstetrics/gynecology vs. urologic surgeons (OR: 1.19, 95% CI: 1.02 - 1.40). Patients in counties with lower per capita income (OR: 1.02, 95% CI: 1.01 - 1.03), lower proportions of foreign-born (OR: 1.01, 95% CI: 1.01 - 1.05), limited English-speaking (OR: 1.03, 95% CI: 1.01 - 1.05), or uninsured (< 64 years of age; OR: 1.02, 95% CI: 1.00 - 1.03) households had higher likelihood of receiving staged surgery. Conclusions: This study identified several demographic, socioeconomic, and surgeon-related factors associated with staged vs. concomitant MUS procedures among patients undergoing surgery for POP. The reasons for these differences are not fully understood and may reflect various underlying factors, including differences in communication, regional or specialty norms, patient choice, or other factors.
- Open Access
- 8 August 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 253, 88-97
Interplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease
- 8 August 2025
- Published by Elsevier in The American Journal of Cardiology
- Vol. 253, 88-97
Open AccessInterplay of Race and Community Characteristics on Health Disparities Among Medicare Beneficiaries With Peripheral Artery Disease
- Open Access
- 7 July 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Rectal spacer use and bowel, urinary, and sexual dysfunction diagnosis and related procedures among men receiving prostate radiotherapy: US county-level analysis
Purpose Clinical studies demonstrate the protective function of rectal spacers to mitigate side effects of radiotherapy (RT) in prostate cancer (PCa) patients. However, large-scale real- world evidence is lacking. This study evaluates the association between rectal spacer use and the prevalence of bowel, urinary, and sexual dysfunction diagnoses and related procedures among PCa patients receiving RT in the US at the county level. Methods Medicare 5% and 100% Standard Analytic Files were used to analyze county-level data from January 2015 to March 2024. The sample included adult PCa patients receiving RT. The primary outcome was the county-level proportion of RT patients diagnosed with bowel, urinary, or sexual dysfunctions or undergoing related procedures. The primary explanatory variable was rectal spacer use 1–5 years before diagnosis. Zero-inflated Poisson regression models were used, controlling for county-level characteristics. Results Among 318,911 PCa patients across 3,168 US counties, the annual prevalence of dysfunction was 2.0% (bowel), 5.6% (urinary), and 1.1% (sexual). Rectal spacer use increased from 4.4 to 18.1% over the study period. A 100-percentage point increase in rectal spacer use at the county level was associated with a 7.1–55.1% reduction in any of three dysfunctions after 1–5 years (all p < 0.05), with similar but weaker trends for related procedures. The strongest association was observed for bowel dysfunction, followed by urinary dysfunction. Conclusion This large-scale, county-level analysis identifies an association between rectal spacer use and lower prevalence of bowel, urinary, and sexual dysfunction, suggesting potential population-level benefits in PCa RT patients.
- 7 July 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Open AccessRectal spacer use and bowel, urinary, and sexual dysfunction diagnosis and related procedures among men receiving prostate radiotherapy: US county-level analysis
Purpose Clinical studies demonstrate the protective function of rectal spacers to mitigate side effects of radiotherapy (RT) in prostate cancer (PCa) patients. However, large-scale real- world evidence is lacking. This study evaluates the association between rectal spacer use and the prevalence of bowel, urinary, and sexual dysfunction diagnoses and related procedures among PCa patients receiving RT in the US at the county level. Methods Medicare 5% and 100% Standard Analytic Files were used to analyze county-level data from January 2015 to March 2024. The sample included adult PCa patients receiving RT. The primary outcome was the county-level proportion of RT patients diagnosed with bowel, urinary, or sexual dysfunctions or undergoing related procedures. The primary explanatory variable was rectal spacer use 1–5 years before diagnosis. Zero-inflated Poisson regression models were used, controlling for county-level characteristics. Results Among 318,911 PCa patients across 3,168 US counties, the annual prevalence of dysfunction was 2.0% (bowel), 5.6% (urinary), and 1.1% (sexual). Rectal spacer use increased from 4.4 to 18.1% over the study period. A 100-percentage point increase in rectal spacer use at the county level was associated with a 7.1–55.1% reduction in any of three dysfunctions after 1–5 years (all p < 0.05), with similar but weaker trends for related procedures. The strongest association was observed for bowel dysfunction, followed by urinary dysfunction. Conclusion This large-scale, county-level analysis identifies an association between rectal spacer use and lower prevalence of bowel, urinary, and sexual dysfunction, suggesting potential population-level benefits in PCa RT patients.
- Open Access
- 3 March 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (3) , e250491
Bowel Disorder Incidence and Rectal Spacer Use in Patients With Prostate Cancer Undergoing Radiotherapy
Importance: The polyethylene glycol-based hydrogel spacer (PHS) system temporarily separates the rectum from the prostate in patients undergoing radiotherapy (RT) for prostate cancer (PCa).Objective: To compare incidence of bowel disorders and related procedures in patients receiving RT with and without PHS.Design, Setting, and Participants: This retrospective cohort study used 4 datasets: Medicare 5% Standard Analytic Files, Medicare 100% Standard Analytic Files, Merative MarketScan Commercial Database, and Premier Healthcare Database. Participants included adult patients with PCa undergoing RT from 2015 to 2021.Exposure: Placement of PHS.Main Outcomes: All-cause bowel disorders and related procedures, identified from diagnosis and procedure codes. Results were compared with age-matched male general population without PCa or RT.Results: Of 261 906 patients with PCa included in the study, 25 167 (9.6%) received PHS (mean [SD] age, 70.7 [6.5] years) and 236 739 did not (mean [SD] age, 71.1 [7.5] years). One year prior to RT, patients who received PHS had a lower mean (SD) Charlson Comorbidity Index score than those who did not (2.48 [1.08] vs 3.14 [1.95]; P < .001). Stereotactic RT was more common in patients who received PHS (2743 [10.9%] vs 8810 [3.7%]; P < .001), while intensity-modulated RT was less common (12 755 [50.7%] vs 142 402 [60.2%]; P < .001). After 4 years post RT, patients who received PHS had a 25% lower hazard of bowel disorders (hazard ratio [HR], 0.75 [95% CI, 0.72-0.78]; P < .001) and a 46% lower hazard of related procedures (HR, 0.54 [95% CI, 0.47-0.62]; P < .001) than patients who did not receive PHS. Patients without PHS had higher hazard compared with an age-matched general population (disorders: 17.1% [95% CI, 17.3%-17.6%] vs 10.3% [95% CI, 10.1%-10.5%]; HR, 1.35 [95% CI, 1.32-1.37]; P < .001; procedures: 2.0% [95% CI, 1.9%-2.1%] vs 0.7% [95% CI, 0.7%-0.8%]; HR, 1.92 [95% CI, 1.79-2.06]; P < .001), while patients who received PHS did not (disorders: 12.4% vs 10.3%; HR, 1.00 [95% CI, 0.98-1.05]; P = .82; procedures: 1.1% [95% CI, 1.0%-1.3%] vs 0.7% [95% CI, 0.7%-0.8%]; HR, 1.11 [95% CI, 0.96-1.29]; P = .15). Common procedures included colonoscopy, sigmoidoscopy, and rectal resection.Conclusions and Relevance: In this cohort study of patients with PCa receiving RT, those receiving a PHS had a significantly lower incidence of all-cause bowel disorders and related procedures compared with patients who did not receive a PHS over the 4-year follow-up. The incidence among patients with PHS was similar to the general population. These findings are consistent with prior phase 3 trial results, where patients receiving PHS experienced no decline in bowel quality of life.
- 3 March 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (3) , e250491
Open AccessBowel Disorder Incidence and Rectal Spacer Use in Patients With Prostate Cancer Undergoing Radiotherapy
Importance: The polyethylene glycol-based hydrogel spacer (PHS) system temporarily separates the rectum from the prostate in patients undergoing radiotherapy (RT) for prostate cancer (PCa).Objective: To compare incidence of bowel disorders and related procedures in patients receiving RT with and without PHS.Design, Setting, and Participants: This retrospective cohort study used 4 datasets: Medicare 5% Standard Analytic Files, Medicare 100% Standard Analytic Files, Merative MarketScan Commercial Database, and Premier Healthcare Database. Participants included adult patients with PCa undergoing RT from 2015 to 2021.Exposure: Placement of PHS.Main Outcomes: All-cause bowel disorders and related procedures, identified from diagnosis and procedure codes. Results were compared with age-matched male general population without PCa or RT.Results: Of 261 906 patients with PCa included in the study, 25 167 (9.6%) received PHS (mean [SD] age, 70.7 [6.5] years) and 236 739 did not (mean [SD] age, 71.1 [7.5] years). One year prior to RT, patients who received PHS had a lower mean (SD) Charlson Comorbidity Index score than those who did not (2.48 [1.08] vs 3.14 [1.95]; P < .001). Stereotactic RT was more common in patients who received PHS (2743 [10.9%] vs 8810 [3.7%]; P < .001), while intensity-modulated RT was less common (12 755 [50.7%] vs 142 402 [60.2%]; P < .001). After 4 years post RT, patients who received PHS had a 25% lower hazard of bowel disorders (hazard ratio [HR], 0.75 [95% CI, 0.72-0.78]; P < .001) and a 46% lower hazard of related procedures (HR, 0.54 [95% CI, 0.47-0.62]; P < .001) than patients who did not receive PHS. Patients without PHS had higher hazard compared with an age-matched general population (disorders: 17.1% [95% CI, 17.3%-17.6%] vs 10.3% [95% CI, 10.1%-10.5%]; HR, 1.35 [95% CI, 1.32-1.37]; P < .001; procedures: 2.0% [95% CI, 1.9%-2.1%] vs 0.7% [95% CI, 0.7%-0.8%]; HR, 1.92 [95% CI, 1.79-2.06]; P < .001), while patients who received PHS did not (disorders: 12.4% vs 10.3%; HR, 1.00 [95% CI, 0.98-1.05]; P = .82; procedures: 1.1% [95% CI, 1.0%-1.3%] vs 0.7% [95% CI, 0.7%-0.8%]; HR, 1.11 [95% CI, 0.96-1.29]; P = .15). Common procedures included colonoscopy, sigmoidoscopy, and rectal resection.Conclusions and Relevance: In this cohort study of patients with PCa receiving RT, those receiving a PHS had a significantly lower incidence of all-cause bowel disorders and related procedures compared with patients who did not receive a PHS over the 4-year follow-up. The incidence among patients with PHS was similar to the general population. These findings are consistent with prior phase 3 trial results, where patients receiving PHS experienced no decline in bowel quality of life.
- Open Access
Risk Factors for Adverse Outcomes Following Ureteroscopy for Stone Management in US Medicare Patients